Shareholders' Claims Narrowed, but Malpractice Suit Against Winston & Strawn May Go Forward

Winston & Strawn must face a $2.5 million malpractice suit from former shareholders of pharmaceutical company Biosynexus for allegedly botching the 2005 sale of the company, a New York judge has ruled.

By |2011-08-24T12:47:09+00:00August 24th, 2011|Uncategorized|Comments Off on Shareholders' Claims Narrowed, but Malpractice Suit Against Winston & Strawn May Go Forward